USFDA gives nod to Zydus Lifesciences for generic rheumatoid arthritis treatment drug
The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing.
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic Indomethacin suppositories indicated for moderate to severe rheumatoid arthritis.
The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing.
The company has been granted 180-day CGT (competitive generic therapy) exclusivity to market this product, it added.
As per the USFDA, it may designate a drug as a CGT after determining that there is inadequate generic competition for that drug.
"We are happy to leverage the CGT approval pathway of the USFDA to provide patients with expanded access to a product with limited competition," Zydus Lifesciences Managing Director Dr Sharvil Patel said.
Zydus said Indomethacin suppositories is a non-steroidal, anti-inflammatory drug indicated for moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Citing IQVIA MAT April 2023 data, the company said Indomethacin suppositories 50mg had annual sales of approximately USD 95 million in the US.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Bank holiday on May 20, Lok Sabha Election 2024: Banks to be closed in these cities on Monday for phase 5 elections
140% return in one year: Brokerage recommends buying this multibagger stock for over 30% returns, know target price
02:56 PM IST